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Molecularimaging,includingﬂuorescenceimaging(FMI),bioluminescenceimaging(BLI),positronemissiontomography(PET),
single-photon emission-computed tomography (SPECT), and computed tomography (CT), has a pivotal role in the process of
tumor and relevant drug research. CT, especially Micro-CT, can provide the anatomic information for a region of interest (ROI);
PETandSPECTcanprovide functionalinformationfortheROI. BLIandFMIcan provide optical informationforan ROI.Tumor
angiogenesis and relevant drug development is a lengthy, high-risk, and costly process, in which a novel drug needs about 10–15
years of testing to obtain Federal Drug Association (FDA) approval. Molecular imaging can enhance the development process
by understanding the tumor mechanisms and drug activity. In this paper, we focus on tumor angiogenesis, and we review the
characteristics of molecular imaging modalities and their applications in tumor angiogenesis and relevant drug research.
1.Introduction
Drug development, especially antitumor drug development,
is a relatively long process. Drug development contains
ﬁve procedures, assessment of target expression, lead com-
pound optimization, pre-Phase 1 studies, clinical Phase 1–3
studies, and Federal Drug Association (FDA) approval [1–
3]. Angiogenesis is one of the fundamental characteristics
during tumor progression and metastasis [4]. Detection of
newborn tumor blood vessels and antiangiogenic drugs are
being widely studied. Traditional biological techniques usu-
ally require euthanasia of experimental animals to acquire
the correlative biological information of interest which make
continuous detection impossible.
In recent years, molecularimaging emergedwith increas-
ing popularityin monitoring thechanges ata molecularlevel
in vivo and in evaluating treatment eﬃcacy much earlier and
much more accurately [5]. In contrast with traditional bio-
logical technology, molecular imaging can provide a whole
body readout in an intact system through a longitudinal
study in the same animals, provided that more statistically
relevant and more accurate results are presented in eval-
uating the eﬃcacy of antitumor drugs [6–8]. Because of
the characteristics of molecular imaging, it can certainly
decrease the workload and speed up drug development.
In this paper, we review the characteristics and principles
of diﬀerent molecular imaging modalities before describing
how molecular imaging can be used in tumor angiogenesis
detection and relevant drug development.
2.CharacteristicsandPrinciplesof
Molecular Imaging
Molecular imaging can monitor biological processes at
cellular and molecular levels in intact living subjects. Optical
molecular imaging, such as bioluminescence imaging (BLI)
and ﬂuorescence imaging, has the advantage of high sensitiv-
ity and low cost. BLI uses light produced by the enzymatic
reaction of a luciferase enzyme and its substrate. Based on
this imaging principle, split-protein strategies were devel-
oped to assess protein-protein interactions in vivo using BLI
techniques [9–19]. By detecting the bioluminescence pho-
tons, we can characterize a variety of cellular and molecular
processes, including protein interactions [20–23], protein
degradation [24–26], and protease activity [27–29]. Oth-
erwise, the ﬁreﬂy luciferase gene could be transferred into
tumorcellsandcouldbeused toevaluatethetumorresponse2 International Journal of Biomedical Imaging




















Figure 1: Serial bioluminescence images of the HCC-LM3-fLuc tumor-bearing nude mice that underwent saline (a) or cyclophosphamide
(b) treatment (data from Ma et al. [6]).
to chemotherapeutic agents in living animals. In Figure 1
[6], we used BLI to evaluate the antitumor eﬃcacy of cy-
clophosphamide in HCC-LM3-fLuc tumor-bearing nude
mice.
After imaging acquisition, we could count the photons
in a region of interest (ROI) to quantify the antitumor eﬃ-
cacy by using WINMI (windows-based molecular imaging),
which was developed based on the medical imaging ToolKit
(MITK[30];MedicalImageProcessing andAnalyzinggroup,
Institute of Automation, Chinese Academy of Sciences,
Beijing, China; http://www.mitk.net/).
The tumor volume was measured using a calendar in
order to evaluate the antitumor eﬃcacy of the drug. How-
ever, conventional measurement with a calendar usually
introduced more induced errors. Through quantiﬁcation of
the light intensity, this BLI technique can provide more
accurate information of tumor progression. However, this
technique can only provide two-dimensional information
on tumor which cannot fulﬁll the need for inner tumor
detection and corresponding drug evaluation. Furthermore,
when combined with computed tomography (CT), we have
developed our prototype system to detect inner tumors
in the mouse. The dual modality system (Micro-CT and
BLI) is shown in Figure 2. Micro-CT can provide three-
dimensional anatomic structure information to form the
heterogeneousmouse which isprovento bemore accuratein
reconstructing the three-dimensional location information
[31]. This technique provides an eﬀective tool for inner
tumor detection and evaluation of antitumor drugs.
In ﬂuorescence imaging (FMI), an external light with an
appropriatewavelengthwasusedtoexciteatargetﬂuorescent
molecule. Then, almost immediately, the target ﬂuorescent
molecules released a longer wavelength, lower-energy light
f o ri m a g i n g .I nc o n t r a s tt oB L I ,t h ed e t e c t i o nd e p t ho fF M I
is greater than a few millimeters by using the near infrared
ﬂuorescence (NIRF) probe and dye [8]. After imaging
acquisition and ﬁltering of the background noises, the high-
contrast images can be obtained. Using the same method
with BLI, the light intensity can be counted to evaluate the
tumor volume and antitumor drug eﬃcacy.
Positron emission tomography (PET) and single-photon
emission-computed tomography (SPECT) are imaging mo-
dalities that are widely used in preclinical and clinical studies
[32, 33]. They can be used to detect the molecular and
cellular changes of diseases before the tumor is large enough
to cause structural changes by injecting radiotracer labeled
probes [34, 35]( s u c ha s18Ff o rP E T ,131If o rS P E C T ) .T h e s e
imaging modalities have been applied not only in rodents or
larger animals, but also in clinical trials, such as for disease
diagnosis [34] and monitored disease therapy [36]. Com-
bined with morphological/anatomical imaging modalities
( s u c ha sC T ) ,P E T / S P E C Tc a nb eu s e dt oo b t a i nt h r e e -
dimensional tomography images and can provide dynamic
functional information. Because of the decay characteristics
of a radionuclide, time-decay calibration was often used
to attain radionuclide uptake per weight for the compar-
ison between diﬀerent tissues. In contrast with BLI/FMI,















tem. (1) CCD camera; (2) X-ray detector; (3) mouse holder; (4) X-
ray tube; (5) anesthesia machine; (6) rotation stage.
with unlimited depth penetration. However, they also share
the limitations of high cost and limited spatial resolution.
CT is widely used in diagnostic medicine as it enables
doctors to provide safe, cross-sectional images with a high
resolution to patients. It uses X-rays for forming tissue
images, and the images are reconstructed from its pro-
jections. A projection means a line integral to the X-ray
attenuation coeﬃcients of the images in a given direction. In
preclinical research, Micro-CT for small animal imaging has
played a critical role in the evolution of molecular imaging
[37]. The X-Ray data was reconstructed based oncone-beam
geometryutilizingaFeldkamp-Davis-Kress(FDK)algorithm
[38], which is an approximate algorithm, and the cone
angle should be limited to a relatively small value to avoid
cone-beam artifacts. Micro-CT can obtain high resolution
anatomicinformationwhichcanintegratewithothermodal-
ities, such as nuclear and optical approaches. Since X-ray
attenuation of soft tissues is diﬀerent from that of bones,
Micro-CT is very suitable for bone detection, such as bone
growth, destruction, and changes in bone density. Despite
lacking a targeted contrast agent, Micro-CT is not able to
acquire molecular imaging directly, but it can indirectly
reﬂect the changes of cells and molecular structures, such
as imaging changes in vascular density [39]. For in vivo
imaging,especially inalongitudinalstudy,theradiation dose
should be considered, and much attention has been paid to
CT imaging with a high resolution as well as a low-radiation
dose.
3.TumorAngiogenesis
Tumor angiogenesis is a process ofproliferation ofa network
of blood vessels that penetrates into cancerous growths, sup-
plying nutrients and oxygen and removing waste products.
Tumor angiogenesis is activated by the signal molecules that
are sent by cancerous tumor cells. These signals activate
certain genes in the host tissue, make proteins, and form the
network of new blood vessels surrounding the tumor. These
signal molecules include, but are not limited to, growth
factor receptors, tyrosine kinase receptors, integrins, and
matrix metalloproteinases [40](MMP).Inthispaper, wewill
focus on two of the most intensively studied angiogenesis-
related molecular targets: vascular endothelial growth factor
(VEGF) and VEGF receptors (VEGFR), and integrin αvβ3.
During tumor angiogenesis, these molecules can be used as
indicators in molecular imaging. By targeting them, we
can diagnose some tumors which express these molecules.
Furthermore,we canevaluatetheantitumoreﬃcacyofdrugs
using the correlative probes.
4.Imaging VEGF/VEGFRExpression
VEGF is a powerful mitogen in embryonic and somatic angi-
ogenesis. Itplaysa pivotalrole in both normal vasculartissue
development and tumor neovascularization. Overexpression
of VEGF is associated with tumor progression and poor
prognosisinseveraltumors,includingcolorectal,gastric,and
pancreatic carcinomas; angiosarcomas; breast, prostate, and
lung cancers; malignant gliomas; melanoma.
Through building a transgenic mouse of a VEGF pro-
moterdrivenGFPreportergene,Izzo’sgroupprovedﬂuores-
cence imaging is credible in detecting the VEGF [41]. After-
wards, Wang’s groupusedBLItodetect VEGF ina transgenic
mouse model [42]. Vascular endothelial growth factor A
(VEGFR-1) and Flk-1/KDR (VEGFR-2) are key regulators
for tumor angiogenesis and tumor growth. Chen’s group
monitored the antiangiogenic and antitumor eﬃcacies of
a vasculature-targeting fusion toxin (VEGF121/rGel) com-
posed of the VEGF-A isoform VEGF121 linked with a G4S
tether to recombinant plant toxin gelonin (rGel) in an
orthotopic glioblastoma mouse model by use of noninvasive
in vivo BLI, magnetic resonance imaging (MRI), and PET.
Through this study, they proved multimodality imaging
and therapy with VEGF121/rGel could provide an eﬀective
means to prospectively identify patients who will beneﬁt
from VEGF121/rGel therapy and then stratify, personalize,
and monitor treatment to obtain optimal survival outcomes
in future clinical applications [43].
As an eﬀective imaging technique, PET has been applied
in the clinical studies. With the development of Micro-PET
scanners dedicated to small animal imaging studies, it can
provide a similar in vivo imaging capability in mice, rats,
monkeys, and humans [44, 45]. As an IgG1 monoclonal
antibody thatbindstohumanVEGF,VG76ewas labeledwith
124I for PET imaging of solid tumor xenografts in immune-
deﬁcient mice [46]. Chen’s group [47] labeled VEGF121
with 64Cu for PET imaging of tumor angiogenesis and
VEGFR expression. This study showed that 64Cu-DOTA-
VEGF121 (∼15%ID/g) had a rapid, speciﬁc, and prominent
uptake in highly vascularized small U87MG tumors with
high VEGFR-2 expression but lower and sporadic uptake
in large U87MG tumors with low VEGFR-2 expression
[47]. In a follow-up study, a VEGFR-2 speciﬁc fusion toxin
VEGF121/rGel (composed of VEGF121 linked with a G4S
tether to the recombinant plant toxin gelonin) was used
to treat orthotopic glioblastoma in a mouse model [48].
In addition, recombinant human VEGF121 was labeled with
111In for SPECT imaging to identify ischemic tissue in a rab-
bit model, where unilateral hind-limb ischemia was created4 International Journal of Biomedical Imaging
by femoral artery excision [49]. Furthermore, VEGF121 has
also been labeled with 99mTc through an “adapter/docking”
strategy,and thetracer was testedin a4T1murine mammary
carcinoma with tumor uptake of about 3%ID/g [50, 51].
5.Imaging αvβ3 Expression
αvβ3 is a member of the integrin family which is a kind of
adhesion molecule consisting of two noncovalently bound
transmembrane subunits (α and β). In mammals, 18α (120–
185KD)and 9β (90–110kd) subunitsassemble into 24 kinds
of diﬀerent receptors. Integrin signaling pathways play a
crucial role in tumor angiogenesis and metastasis. Tumor
growth, angiogenesis, and metastasis can be inhibited by
blocking integrin signaling. Integrin αvβ3 is an important
indicator in evaluating the antitumor eﬃcacy of drugs to
the αvβ3 positive tumors. Some antibodies, peptides, pep-
tidomimetics, and other antagonists have been proven to
have great potential in the treatment of cancer.
Integrin αvβ3 is often expressed on some tumor cells in
the brain, such as glioblastoma multiforme, and striatum
neutral stem-cells-derived primary tumor. Via radiotracer
labeling of some ligands or antibodies, the expression of
integrinαvβ3 canbeimagedbyMicro-PETorSPECT[52].In
Jia’s research [53], a 99mTc-Labeled cyclic RGDfK dimer has
been studied to evaluate its application for SPECT imaging
of glioma integrin αvβ3 expression. They found that glioma
tumors could be clearly visualized with all three radiotracers
at 4h after injection and 99mTc(SQ168)(tricine)(TPPTS)
(∗(SQ168) [2-[[[5-[carboonyl]-2-pyridinyl]-hydrazono]
methyl] benz-enesulfonic acid]-Glu(cyclo{Lys-Arg-Gly-
Asp-D-Phe})-cyclo{Lys-Arg-Gly-Asp-D-Phe})h a dt h eb e s t
imaging quality among the three radiotracers [53]
([99mTc(SQ168)(EDDA)], [99mTc(SQ168)(tricine)(PDA)],
and [99mTc(SQ168)(tricine)(TPPTS)] (SQ168 =[2-[[[5-
[carboonyl]-2-pyridinyl]-hydrazono]methyl]benzenesulfo-
nic acid]-Glu (cyclo{Lys-Arg-Gly-Asp-D-Phe})-cyclo{Lys-
Arg-Gly-Asp-D-Phe};E D D A= ethylenediamine-N,N -
diacetic acid; PDA = 2,5-pyridinedicarboxylic acid; TPPTS =
trisodium triphenylphosphine-3,3 ,3  -trisulfonate). 99mTc-
labeled RGD has also been used in gamma imaging of
secondary tumors of transplanted human fetal striatal
neutral stem-cells-derived primary tumor cells [54]. The
results showed both PET and SPECT could be used in
imaging tumorigenesis and metastasis of integrin αvβ3
positive tumors. Some other radiotracers included 18F-
[55, 56], 68Ga- [57], and 64Cu-[58] labeled RGD that were
applied in imaging the integrin αvβ3 expression using PET
or SPECT. All of the radiotracers also validated the potential
value in preclinical and clinical studies. In Cao’s research
[58], 64Cu-labeled RGD was used in imaging teratoma
formation derived from hES cells by targeting αvβ3 integrin
inanudemouse.Furthermore,bycomparingittoBLI, 64Cu-
DOTA-RGD4 proved to have the ability of noninvasively
visualizing teratoma formation in vivo.C o m p a r e dw i t ht h e
two other probes, 18F-labeled FLT and 18F-Labeled FDG,
64Cu-DOTA-RGD4 has a higher sensitivity and tumor to
background contrast (data shown in Figure 3). 90Y-[59]a n d
111IN-[60] labeled monoclonal antibody abegrin had also
beenstudiedin imagingαvβ3 expressionofU87glioblastoma
multiforme.
Otherwise, ﬂuorescent dye-labeled E [PEG4-c(RGDfK)]2
had been developed to image integrin αvβ3 expression by
Liu and his coworkers [61]. By comparing the characteri-
zation of dye-labeled E [PEG4-c(RGDfK)]2 with dye-labeled
RGD dimer without PEG4 linkers, Cy5.5-labeled E [PEG4-
c(RGDfK)]2 showed highertumoraccumulationand tumor-
to-background contrast (data shown in Figure 4). In vivo
NIRF imaging with IRDye800 E [PEG4-c(RGDfK)]2 was
conﬁrmed to oﬀer an easy, fast, and low-cost way to detect
and semiquantify tumor integrin αvβ3 expression in living
subjects.
Integrin αvβ3 is one of the most extensively studied
molecular targets involved in tumor angiogenesis [62–65].
Markiewicz’s group had discovered a presumably inactive
linear hexapeptide GRDSPK with near-IR carbocyanine
molecular probe yielding Cyp-GRD which could be used to
target integrin αvβ3-positive tumors [66]. They later synthe-
sized and evaluated a series of multimeric RGD compounds
constructed on a dicarboxylic acid-containing near-IR ﬂu-
o r e s c e n td y ec y p a t ef o rt u m o rt a r g e t i n g[ 67]. Furthermore,
optimization of the spatial alignment and ligand recon-
structed of the RGD moieties through careful molecular
design may induce multivalent ligand-receptor interactions
useful for in vivo tumor imaging and tumor-targeted ther-
apy. As a humanized monoclonal antibody against human
integrin αvβ3 (picomolar binding aﬃnity), abegrin (MEDI-
522, also called Vitaxin; MedImmune, Inc., Gaithersburg,
Md) is used in clinical trials for cancer therapy. Tice’s group
had conjugated abegrin with macrocyclic chelating agent
DOTA and labeled it with 64Cu for PET imaging of a tumor
xenograft [68].Numerousreportsonmultimodalitymolecu-
lar imaging of integrin αvβ3 showed that tumor angiogenesis
imaging can participate in multiple stages of the drug devel-
opment process, including target validation, lead compound
optimization, compound screening, and clinical trials.
6.ConclusionandPerspective
Molecular imaging has been widely applied in preclinical
studies using some radiotracer probes, and PET and SPECT
have been used in clinical diagnoses and antitumor evalu-
ation of some drugs. However, optical molecular imaging
especially BLI can only be used in preclinical studies. Many
problems can be solved by applying molecular imaging in
clinical research.
BLI has more widely used applications in tumor detec-
tion and evaluation of pharmacodynamics, toxicity, and
pharmacokinetics because of its noninvasive molecular and
cellular level detection ability, high sensitivity, and low cost
in comparison with other imaging technologies. However,
BLI cannot present the accurate location and intensity of
the inner bioluminescent sources such as in the bone,
liver, or lungs. Bioluminescent tomography (BLT) shows its
advantages in determining the bioluminescent source distri-






























Figure 3: Micro-PET imaging of 18F-FDG, 18F-FLT, and 64Cu-DOTA-RGD4 on hES cell-derived teratoma. (a) Background imaging and
bioluminescence imaging show teratoma formation in H9Hes-DF cells in the right shoulder and tumor formation in the control 2008 cell
line in the left shoulder (7.3 ± 2.5 × 10
7 versus 4.5 ± 1.6 ×10
7 photon/s/cm2/sr, resp.); (b) speciﬁc and prominent uptake of 64Cu-DOTA-
RGD4 was found in the vascularized teratoma but not in the control human ovarian carcinoma 2008 cell line with low integrin expression
(P<0.01); (c) hES cell-derived teratomas had a low uptake of 18F-FLT, whereas the 2008 cancer xenografts exhibited high 18F-FDG and
18F-FLT uptakes; (d) hES cell-derived teratomas had a low uptake of 18F-FDG, whereas the 2008 cancer xenografts and abdomen exhibited













Figure 4: In vivo ﬂuorescence imaging of U87MG tumor-bearing nude mice at 1, 2, and 4 hours after intravenous injection of 0.5 nmol
IRDye800-RGD2 or IRDye800-PEG4-RGD2. Fluorescence signal from IRDye800 is pseudocolored (data from Liu et al. [61]).
information acquired by an X-ray detector, the three-di-
mensional location can be reconstructed using some BLT
reconstruction methods such as the adaptive ﬁnite element
method and Bayesian method These tomography imaging
methods can be used in early detection of tumors [69]a n d
assist in the diagnosis and evaluation of drug eﬃcacy more
accurately.Furthermore,theclinicalapplicationofBLIneeds
to develop some novel probes which can be used in humans.
Developing a novel imaging probe is an expensive, time-
consuming procedure.
For PET/SPECT imaging, some radiotracers such as 18F,
64Cu, 111In, and 68Ga have been used in labeling ligands
and antibodies to image their relative receptors. However,
the binding ability between some radiotracers, their ligands,
and antibodies is low. Some single-targeted probes have
poor pharmacokinetic properties with fast clearance speed.
Furthermore, with the development of molecular imaging,
some new dual-modality ormultimodality probesneed to be
developed to acquire more general, more accurate informa-
tion of the disease. In recent years, signiﬁcant advances have6 International Journal of Biomedical Imaging
been made in developing novel probes for multimodality
molecular imaging of tumor angiogenesis. Among all of
the studies regarding multimodality probes, multireceptor-
targeted imaging probes are most popular with some
advantages. First of all, because some receptors may not be
suﬃciently expressed in all tumor cells during tumor pro-
gression and processes, with multireceptor targeting, more
probes can accumulate in tumor cells and tissues. Secondly,
the binding aﬃnity of multireceptor-targeted probes can
be relatively higher than in single receptor targeted probes.
Thirdly, the clearance properties and excretion rates of dual-
or multireceptor-targeted probes may be optimal compared
to single receptor-targeted probes. In general, develop-
ing novel, high-aﬃnity probes is necessary for molecular
imaging.
In summary, although imaging to tumor angiogenetic
and relevant drugs have been reported in previous work,
tumor angiogenesis and relevant drug studies are subject to
many problems, such that a good probe for imaging VEGF/
VEGFR is limited which greatly hinders the development of
imaging; imaging sensitivity needs to be improved which
can help in determining whether or not to start and when
to start VEGFR-targeted treatment. Accordingly, research on
the following two aspects need to be strengthened in the
future.
Based on the current probe, the development of a more-
sensitive, less-toxic multimodal molecular imaging probe is
necessary.
Based on the current imaging technique, the develop-
mentofmoreaccurateimageprocessingalgorithmsisthekey
to VEGF/VEGFR and relevant drug studies.
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